Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linaclotide in Minimal Hepatic Encephalopathy
jRCTs031200163Phase 2Recruiting
- Start
- Jan 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of linaclotide in hepatic encephalopathy (HE), Cirrhosis and chronic liver disease (CLD). Primary endpoint: Improvement of number connection test-A. Started Jan 2021; status: recruiting.
02
Drugs
linaclotide
03
Conditions
hepatic encephalopathy (HE)Cirrhosischronic liver disease (CLD)
Beyond the preview
Go deeper on jRCTs031200163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200163.